Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?

Roseman, C; Wallman, J K; Jöud, A; Schelin, Mec; Einarsson, J T; Lindqvist, E; Lampa, J; Kapetanovic, M C; Olofsson, T

Roseman, C; Wallman, J K; Jöud, A; Schelin, Mec; Einarsson, J T; Lindqvist, E; Lampa, J; Kapetanovic, M C; Olofsson, T.

Affiliation

Roseman C; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
Wallman JK; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
Jöud A; Department of Laboratory Medicine, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.
Schelin M; Department of Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden.
Einarsson JT; Department of Research and Development, Skåne University Hospital, Lund, Sweden.
Lindqvist E; The Institute for Palliative Care, Lund University and Region Skåne, Lund, Sweden.
Lampa J; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
Kapetanovic MC; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
Olofsson T; Karolinska Institute, Department of Medicine Solna, Rheumatology Unit, Center of Molecular Medicine (CMM), Stockholm, Sweden.

Scand J Rheumatol ; 53(2): 94-103, 2024 Mar.

Article in En | MEDLINE | ID: mdl-38031733

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pain, Intractable / Arthritis, Psoriatic / Antirheumatic Agents Limits: Humans Language: En Journal: Scand J Rheumatol Year: 2024 Document type: Article Affiliation country:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google